Pfizer’s VYNDAQEL® (tafamidis) receives positive CHMP opinion
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of...
ABPI responds to General Election result
The ABPI has responded to the General Election result welcoming the news and saying that it is looking forward to working with the new...
Breast cancer blood test could help target treatment
A breast cancer blood test can help identify rare mutations in advanced breast cancer and may enable patients to access effective treatments more quickly...
Janssen presents initial results for BCMA CAR-T therapy
Janssen presents initial results for BCMA CAR-T therapy JNJ-4528 showing early, deep and high responses in the treatment of relapsed or refractory multiple myeloma. The...
Servier and UCL collaborate on immune-inflammatory disease treatments
Accelerating the discovery of new treatments for immune-inflammatory disease, including lupus and systemic sclerosis, is the focus of a new strategic research collaboration between...
Forendo and Novartis partner on novel chronic liver disease treatments
Forendo and Novartis are to partner on novel chronic liver disease treatments. Forendo Pharma, a clinical stage drug development company focusing on novel treatments...
Kite announces new Yescarta® data from pivotal ZUMA-1 trial
Kite announces new Yescarta® data from pivotal ZUMA-1 trial. The new data from the pivotal ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) showed that approximately...
AstraZeneca and MSD’s Lynparza™ now available in Scotland
AstraZeneca and MSD's Lynparza™ is now available in Scotland as the companies announce that olaparib monotherapy is now accepted for use by the Scottish...
Novartis highlights progress in R&D pipeline
Novartis is holding an investor event to provide a comprehensive overview of the company’s progress in advancing its R&D pipeline. Key highlights to be presented...
MSD’s new HIV-1 treatment approved for use on the NHS
MSD's new HIV-1 treatment has been approved for use on the NHS. MSD has announced that its new treatment for HIV-1 infection – doravirine▼...
Latest articles
What’s been authorised? UK, Europe, US drug approvals
Pf summarises the UK, Europe and US drug approvals from 20 - 24 Jan 2020. UK The National Institute for Health and Care Excellence published draft...
Digital interventions for behaviour change
New NICE guidance looks at digital interventions for behaviour change and suggests that these interventions such as apps, wearable devices and online programmes and...
Acute aortic dissection is a ‘ticking time bomb’
Safety body calls for earlier recognition of ‘ticking time bomb’ aortic dissection to prevent deaths as its new report reveals that up to half...
Popular articles
NICE rejects Janssen’s Stelara for moderate to severe ulcerative colitis
The National Institute for Health and Care Excellence (NICE) has not recommended ustekinumab, Janssen's Stelara, for treating moderately to severely active ulcerative colitis in...
Meningitis B infant vaccination programme shows 75% drop in cases over three years
Meningitis B infant vaccination programme shows 75% drop in cases over three years, these are the results of one of two independent meningitis B...
Integrated commercial deployment in life sciences and other 2020 health trends
Syneos Health explore integrated commercial deployment in life sciences and discuss their new report covering 2020 health trends. Life science leaders aren’t launching with...
AstraZeneca’s Tagrisso▼ (osimertinib) rejected by NICE for use in NHS England
The National Institute for Health and Care Excellence (NICE) has published final guidance that does not recommend AstraZeneca's Tagrisso▼ (osimertinib) for use within NHS...
What’s been authorised? UK, Europe, US drug approvals
Pf summarises the UK, Europe and US drug approvals from 20 - 24 Jan 2020. UK The National Institute for Health and Care Excellence published draft...